Isofol Medical: Waiting for AGENT read-out - DNB

Isofol Medical released its Q4 report on 24 February. The report was a non-event, in our view. In Q4, the company announced that it would not reach 300 PFS events (the original trigger for closing the trial) as too many patients had moved on to new treatments without a confirmed event. The company is in discussions with the FDA on what should trigger the breaking of the code in the trial. Overall, the company plans for data read-out in late Q2. Following a change of analyst, we now estimate the fair value for the Isofol Medical share at SEK14–26 (13–23).

Länk till analysen i sin helhet: https://www.dnb.no/seg-fundamental/fundamentalweb/GetReportSpon.aspx?file=CMPSP_190557.pdf